Credit Suisse Maintains Neutral Rating for Beam Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Credit Suisse has maintained its Neutral rating for Beam Therapeutics (NASDAQ:BEAM) and increased its price target from $46.00 to $47.00. Beam Therapeutics' shares are currently trading down 0.76% at $26.05 per share. A move to $47.00 would represent an 80.42% increase from the current share price.
August 09, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Credit Suisse has maintained its Neutral rating for Beam Therapeutics and raised its price target. This could potentially influence investor sentiment and the stock's price.
Analyst ratings and price targets can significantly influence investor sentiment and the stock's price. While the Neutral rating suggests that Credit Suisse does not expect significant price movement, the raised price target could potentially signal an upside, which might positively influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100